Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MeVis Medical Solutions AG has the GF Score of 73, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes MeVis Medical Solutions AG
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
MeVis Medical Solutions AG (STU:M3V) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
MeVis Medical Solutions AG GF Score Related Terms
STU:M3V vs VEEV, BTSG, TEM: GF Score Comparison
For the Health Information Services subindustry, MeVis Medical Solutions AG's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeVis Medical Solutions AG GF Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MeVis Medical Solutions AG's GF Score distribution charts can be found below:
* The bar in red indicates where MeVis Medical Solutions AG's GF Score falls into.
MeVis Medical Solutions AG (STU:M3V) has a GF Score of 73 as of Jul. 14, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on MeVis Medical Solutions AG and its competitors. This is near median its historical median of 71.00. Over the past decade, MeVis Medical Solutions AG's GF Score has ranged from 30.00 to 85.00.
Is MeVis Medical Solutions AG's GF Score too high?
MeVis Medical Solutions AG's current GF Score of 73 is near median its 10-year median of 71.00. Over the past 10 years, this metric has ranged from a low of 30.00 to a high of 85.00. Overall, MeVis Medical Solutions AG has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's GF Score compare to VEEV and BTSG?
MeVis Medical Solutions AG's GF Score of 73 can be compared against companies in the Healthcare Providers & Services industry. Historically, MeVis Medical Solutions AG's own GF Score has ranged from 30.00 to 85.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Healthcare Providers & Services company?
A good GF Score depends on the Healthcare Providers & Services industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on MeVis Medical Solutions AG and its competitors. MeVis Medical Solutions AG's current GF Score is 73, which is near median its own 10-year median of 71.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
Based on GuruFocus' analysis, MeVis Medical Solutions AG (STU:M3V) is currently considered Fairly Valued. The stock's GF Value™ is €22.38, compared to a current price of €23.80 — trading 6.3% above its estimated fair value. The current GF Score is 73, which is near median its 10-year median of 71.00. MeVis Medical Solutions AG's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For MeVis Medical Solutions AG (STU:M3V), the current GF Score is 73 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeVis Medical Solutions AG (STU:M3V) Overvalued in 2026?
Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued.
The current stock price of €23.80 is trading 6.3% above its estimated GF Value™ of €22.38.
GuruFocus considers MeVis Medical Solutions AG to be Fairly Valued.
Key valuation signals for STU:M3V:
GF Score: 73 (near median its 10-year median of 71.00)
GF Value™: €22.38 vs. price of €23.80 (6.3% above fair value)
No single metric tells the full story. See the STU:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
73GF Score
Get the complete analysis for STU:M3V
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:M3V has been successfully added to your 
